Q-omics provides the consensus-scored P2RY6 profile across patient tissues and cancer cell-line models. P2RY6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, P2RY6 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, P2RY6 RNA expression shows 17,341 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, THCA, and LSCC as cancer lineages where P2RY6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RY6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RY6 survival associations across molecular data types. P2RY6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RY6 RNA expression–survival associations across cancer types. High P2RY6 expression shows unfavorable associations in KIRC, UVM, LGG, LIHC and HNSC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for P2RY6 RNA expression.
This table summarizes P2RY6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for P2RY6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RY6 shows higher tumor expression in THCA, KIRC, LUAD, LUSC, HNSC and STAD. The THCA box plot shows higher P2RY6 RNA expression in tumor versus normal tissue (log2 FC = +1.985, t-test p < 0.001).
This table shows molecular features associated with P2RY6 in patient tissues and cancer cell lines. In patient samples, P2RY6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RY6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
